The FDA’s emerging framework represents more than a regulatory update; it is a paradigm shift toward human-relevant, ...
Seeking to develop novel medicines for cardiovascular disease, Novartis and ProFound Therapeutics have signed a four-year strategic collaboration. The agreement will allow the partners to combine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback